![]() “While I really loved real estate, I was more interested in the closing part,” she recalled. Her career started out working with Tommy Adams at Rise Real Estate as his assistant. His hometown was Owens Cross Roads, and Wendy considers the Huntsville area her true home. I like being a part of someone’s dream.”īorn in Chicago where her mom hailed from, Wendy’s parents moved back to the Huntsville area when Wendy was two, as her dad wanted to raise his family in the South. “My favorite part of my work is when we hand them their keys. Wendy answers her phone after hours and on weekends, understanding that the busy schedules of her clients demand that level of high-touch service. They are the rare title company offering “travel closings.” If the customer cannot come to them, they go to their clients. Even prior to her cancer, Valley Title and Closing was renowned for being attentive to their customers. To say Wendy is accommodating to her customers is a bit of an understatement. I just want to make sure my clients are happy.” “I want to continue servicing the clients as well as I do now. Subjects who have an active, known or suspected autoimmune disease.Surviving cancer-twice-has made Valley Title and Closing Services, LLC founder Wendy Worley’s focus on being even more present and in the moment to those around her. Requires treatment with strong CYP3A inhibitors known bleeding disorders or Major surgery within 4 weeks of first dose of study drug History of stroke or intracranial hemorrhage within 6 months prior to enrollment Concomitant use of warfarin or other Vitamin K antagonists Cetuximab or panitumumab (CRC cohort 4) Any taxane ( UC cohort of ibrutinib + paclitaxel) (cohort 2) Everolimus or temsirolimus (RCC cohort 1) Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault) docetaxel is administered, these subjects must have bilirubin within normal origin, such as hemolysis) with the exception of subjects in the GC cohort where Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of Alkaline phosphatase <3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present limit of normal (ULN) if liver metastases, or ≤3 x ULN without liver metastases Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤5.0 x upper Adequate hepatic and renal function defined as: Hemoglobin ≥9.0 g/dL for cohort 4 (CRC) ![]() ![]() for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC) Platelet counts >100,000 cells/mm3 (100 x 109/L) for all UC cohorts Absolute neutrophil count ≥1500 cells/mm3 (1.5 x 109/L) For CRC: minimum of 2 and maximum of 4 prior regimens, which must have included bothĪn irinotecan and an oxaliplatin based regimen unless unable to tolerate irinotecan Which must have included a fluoropyrimidine regimen For gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior regimens one of Of neo- or adjuvant therapy with a platinum chemotherapy. Locally advanced or mUC who have progressed on platinum chemo or within 12 months ![]() Score (CPS) of ≥ 10 without prior treatment. Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1 For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have For RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which must have Gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or Phase 2: To assess the ORR of ibrutinib combination therapy in GC, CRC, UC cohort 6, and ibrutinib as a single agent in UC cohort 5 Phase 2: To assess progression-free survival (PFS) of ibrutinib in combination with everolimus in RCC, and ibrutinib in combination with paclitaxel for UC cohort 2. Phase 1b: To confirm the RP2D of single-agent ibrutinib in UC cohort 5 Phase 1b: To determine the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in UC cohort 2, docetaxel in GC, cetuximab in CRC, and pembrolizumab in UC cohort 6 The purpose of this study is to evaluate the safety, tolerability, and efficacy of singleĪgent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel,ĭocetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary Grants and Research Funding Opportunities. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |